src: thumbor.forbes.com
Larotrectinib (LOXO-101, ARRY-470) is an experimental drug for the treatment of cancer. It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC. It was discovered by Array BioPharma and licensed to Loxo Oncology in 2013.
Larotrectinib was awarded orphan drug status in 2015 for soft tissue sarcoma and breakthrough therapy designation in 2016 for the treatment of metastatic solid tumors with NTRK fusion.
Phase II clinical trials evaluating the drug for efficacy and safety in treating several types of solid tumors are ongoing.
Some clinical trial results were announced in 2017.
Video Larotrectinib
References
Maps Larotrectinib
External links
- Larotrectinib - AdisInsight
Source of article : Wikipedia
0 Comments
